Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707 | Director · President & CEO | November 01, 2024 | November 04, 2024 |
| RESMED INCRMD · Entity 2692 | Director | November 25, 2025 | November 26, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTEGRA LIFESCIENCES HOLDINGS CORP
Report date November 01, 2024 · Filed November 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,902 |
Ending reported balance
After 2024-11-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-11-01 · Exercise / conversion · Acquired 9,814 · Balance 28,164 F1: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The second installment vested on 11/1/2024. Row 2 · 2024-11-01 · Tax withholding · Disposed 4,262 · Balance 23,902 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 120,466 |
Reported balance
After 2024-11-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-11-01 · Exercise / conversion · Disposed 9,814 · Balance 120,466 F1: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The second installment vested on 11/1/2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The second installment vested on 11/1/2024.
RESMED INC
Report date November 25, 2025 · Filed November 26, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ReMed Common StockSEC Table I · non-derivative | Direct | 4,261 |
Reported balance
After 2025-11-25 transaction · row 1
1 source rowRow 1 · 2025-11-25 · Sale · Disposed 2,055 · Balance 4,261 F1: The transaction was conducted under a Rule 10b5-1 plan adopted on August 18, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was conducted under a Rule 10b5-1 plan adopted on August 18, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 25, 2025 Filed Nov 26, 2025 19:40 UTC | RESMED INC RMD · Entity 2692 | SaleReMed Common Stock | 2,055 | $255.00 | $524,025.00 |
DisclosureSEC source: 0000943819-25-000181 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,261 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted on August 18, 2025. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:45 UTC | RESMED INC RMD · Entity 2692 | GrantReMed Common Stock | 1,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000166 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,316 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:24 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingReMed Common Stock | 76.449 | $250.10 | $19,119.89 |
DisclosureSEC source: 0000943819-25-000115 · form4.xml · nonDerivative · entry 2 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,242 F2 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:24 UTC | RESMED INC RMD · Entity 2692 | SaleReMed Common Stock | 487 | $250.25 | $121,871.75 |
DisclosureSEC source: 0000943819-25-000115 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,319 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted Feb 03, 2025. Read SEC document |
| May 20, 2025 Filed May 22, 2025 14:05 UTC | RESMED INC RMD · Entity 2692 | SaleReMed Common Stock | 2,000 | $243.47 | $486,940.00 |
DisclosureSEC source: 0001127602-25-015264 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,806 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 3, 2025. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:22 UTC | RESMED INC RMD · Entity 2692 | GrantReMed Common Stock | 1,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-027902 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,806 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2025, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 16:49 UTC | RESMED INC RMD · Entity 2692 | SaleReMed Common Stock | 796 | $248.81 | $198,052.76 |
DisclosureSEC source: 0001127602-24-027277 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,723 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 2, 2024. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:33 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units · Derivative | 9,814 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000917520-24-000109 · wk-form4_1730755987.xml · derivative · entry 3 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,466 Underlying: Common Stock · 9,814 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The second installment vested on 11/1/2024. F1 · derivative.expiration_date: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The second installment vested on 11/1/2024. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:33 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 4,262 | $19.28 | $82,171.36 |
DisclosureSEC source: 0000917520-24-000109 · wk-form4_1730755987.xml · nonDerivative · entry 2 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,902 Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:33 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 9,814 | $0.00 | $0.00 |
DisclosureSEC source: 0000917520-24-000109 · wk-form4_1730755987.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The second installment vested on 11/1/2024. Read SEC document |
| May 15, 2024 Filed May 17, 2024 15:27 UTC | RESMED INC RMD · Entity 2692 | SaleReMed Common Stock | 360 | $218.29 | $78,584.40 |
DisclosureSEC source: 0001127602-24-015777 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,519 Read SEC document |
| May 15, 2024 Filed May 22, 2024 18:51 UTC Amendment | RESMED INC RMD · Entity 2692 | SaleReMed Common Stock | 360 | $218.29 | $78,584.40 |
DisclosureSEC source: 0001127602-24-016231 · form4a.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,519 F1 · kind: Amended to indicate that the transaction was conducted under a Rule 10b5-1 plan adopted February 2, 2024. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 20:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units · Derivative | 205 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000917520-24-000037 · wk-form4_1710361820.xml · derivative · entry 5 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,280 Underlying: Common Stock · 205 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 of which the second installment vested on 3/11/2024 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation. F3 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 of which the second installment vested on 3/11/2024 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation. F3 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 of which the second installment vested on 3/11/2024 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 20:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantRestricted Stock Units · Derivative | 41,414 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000917520-24-000037 · wk-form4_1710361820.xml · derivative · entry 4 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,485 Underlying: Common Stock · 41,414 shares Expires not disclosed F2 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2024 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F2 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2024 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F2 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2024 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 20:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon- Qualified Stock Option (right to buy) · Derivative | 95,664 | $0.00 Strike: $36.22 | $0.00 |
DisclosureSEC source: 0000917520-24-000037 · wk-form4_1710361820.xml · derivative · entry 3 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,664 Underlying: Common Stock · 95,664 shares Expires 2032-03-11 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/11/2024. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 20:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 205 | $36.22 | $7,425.10 |
DisclosureSEC source: 0000917520-24-000037 · wk-form4_1710361820.xml · nonDerivative · entry 2 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,350 Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 20:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 205 | $0.00 | $0.00 |
DisclosureSEC source: 0000917520-24-000037 · wk-form4_1710361820.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 21:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units · Derivative | 346 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000917520-24-000025 · wk-form4_1710277910.xml · derivative · entry 3 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,071 Underlying: Common Stock · 346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/10/2023 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F1 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/10/2023 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F1 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/10/2023 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 21:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 346 | $36.73 | $12,708.58 |
DisclosureSEC source: 0000917520-24-000025 · wk-form4_1710277910.xml · nonDerivative · entry 2 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,350 Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 21:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 346 | $0.00 | $0.00 |
DisclosureSEC source: 0000917520-24-000025 · wk-form4_1710277910.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 21:43 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units · Derivative | 597 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000917520-24-000002 · wk-form4_1705700588.xml · derivative · entry 3 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,417 Underlying: Common Stock · 597 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The award was a restricted stock unit award which vests in three annual equal installments on the first, second and third anniversaries of the grant date of 1/18/2022 of which the second installment vested on 1/18/2024 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation. F1 · derivative.exercise_date: The award was a restricted stock unit award which vests in three annual equal installments on the first, second and third anniversaries of the grant date of 1/18/2022 of which the second installment vested on 1/18/2024 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation. F1 · derivative.expiration_date: The award was a restricted stock unit award which vests in three annual equal installments on the first, second and third anniversaries of the grant date of 1/18/2022 of which the second installment vested on 1/18/2024 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 21:43 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 597 | $42.39 | $25,306.83 |
DisclosureSEC source: 0000917520-24-000002 · wk-form4_1705700588.xml · nonDerivative · entry 2 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,350 Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 21:43 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 597 | $0.00 | $0.00 |
DisclosureSEC source: 0000917520-24-000002 · wk-form4_1705700588.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:25 UTC | RESMED INC RMD · Entity 2692 | GrantReMed Common Stock | 1,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028090 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,879 F1 · shares: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2024, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:27 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units · Derivative | 9,814 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054323 · doc4.xml · derivative · entry 3 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,014 Underlying: Common Stock · 9,814 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The first installment vested on 11/1/2023. F1 · derivative.expiration_date: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The first installment vested on 11/1/2023. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:27 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 4,262 | $36.85 | $157,054.70 |
DisclosureSEC source: 0001209191-23-054323 · doc4.xml · nonDerivative · entry 2 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,350 Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:27 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 9,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054323 · doc4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On November 1, 2022, the reporting person was granted a restricted stock unit award which vests in three equal annual installments on the first, second and third anniversaries of the grant date of 11/01/2022 and which convert into shares of common stock on a one-for-one basis. The first installment vested on 11/1/2023. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | PurchaseCommon Stock | 7,792 | $38.50 | $299,985.77 |
DisclosureSEC source: 0001209191-23-033676 · doc4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,798 F1 · price: The price shown above represents the weighted average price of the shares purchased. The range of the purchase prices was $38.46 to $38.50. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| March 11, 2023 Filed Mar 14, 2023 20:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 3,842 | $52.87 | $203,126.54 |
DisclosureSEC source: 0001209191-23-018446 · doc4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,006 Read SEC document |
| March 11, 2023 Filed Oct 13, 2023 20:25 UTC Amendment | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units · Derivative | 205 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-052775 · doc4a.xml · derivative · entry 3 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,828 Underlying: Common Stock · 205 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was inadvertently omitted from the Reporting Person's Form 4 filed on March 14, 2023. F2 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 which shall be delivered to the Reporting Person within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F2 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 which shall be delivered to the Reporting Person within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. F2 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 which shall be delivered to the Reporting Person within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. Read SEC document |
| March 11, 2023 Filed Oct 13, 2023 20:25 UTC Amendment | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 205 | $52.87 | $10,838.35 |
DisclosureSEC source: 0001209191-23-052775 · doc4a.xml · nonDerivative · entry 2 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,006 F1 · security: This transaction was inadvertently omitted from the Reporting Person's Form 4 filed on March 14, 2023. Read SEC document |
| March 11, 2023 Filed Oct 13, 2023 20:25 UTC Amendment | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 205 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-052775 · doc4a.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was inadvertently omitted from the Reporting Person's Form 4 filed on March 14, 2023. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantRestricted Stock Units · Derivative | 26,008 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018446 · doc4.xml · derivative · entry 3 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,033 Underlying: Common Stock · 26,008 shares Expires not disclosed F2 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/10/2023 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F2 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/10/2023 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F2 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/10/2023 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:20 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 63,717 | $0.00 Strike: $52.87 | $0.00 |
DisclosureSEC source: 0001209191-23-018446 · doc4.xml · derivative · entry 2 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,717 Underlying: Common Stock · 63,717 shares Expires 2031-03-10 F1 · derivative.exercise_price: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/10/2023. F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/10/2023. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:35 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 8,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009758 · doc4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,848 F1 · shares: On February 13, 2023, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2022 under the March 11, 2022 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 11, 2023, the first anniversary of the grant date. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 21:17 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionRestricted Stock Units · Derivative | 431 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004012 · doc4.xml · derivative · entry 3 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,025 Underlying: Common Stock · 431 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The award was a restricted stock unit award which vests in three annual equal installments on the first, second and third anniversaries of the grant date of 1/18/2022 of which the first installment vested on 1/18/2023 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation. F1 · derivative.exercise_date: The award was a restricted stock unit award which vests in three annual equal installments on the first, second and third anniversaries of the grant date of 1/18/2022 of which the first installment vested on 1/18/2023 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation. F1 · derivative.expiration_date: The award was a restricted stock unit award which vests in three annual equal installments on the first, second and third anniversaries of the grant date of 1/18/2022 of which the first installment vested on 1/18/2023 and which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six-month period after the date of his separation of service as deferred compensation. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 21:17 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 431 | $54.78 | $23,610.18 |
DisclosureSEC source: 0001209191-23-004012 · doc4.xml · nonDerivative · entry 2 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 21:17 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 431 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004012 · doc4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2022 Filed Nov 21, 2022 21:33 UTC | RESMED INC RMD · Entity 2692 | GrantReMed Common Stock | 1,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026159 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,111 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2023, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantRestricted Stock Units · Derivative | 29,441 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-055496 · doc4.xml · derivative · entry 1 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,456 Underlying: Common Stock · 29,441 shares Expires not disclosed F1 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 11/1/2022 and which shall be delivered to Mr. De Witte within 30 days of the vesting of each installment. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F1 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 11/1/2022 and which shall be delivered to Mr. De Witte within 30 days of the vesting of each installment. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F1 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 11/1/2022 and which shall be delivered to Mr. De Witte within 30 days of the vesting of each installment. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 20:40 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantRestricted Stock Units · Derivative | 15,359 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-018841 · doc4.xml · derivative · entry 2 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,015 Underlying: Common Stock · 15,359 shares Expires not disclosed F2 · derivative.exercise_price: The award was a restricted stock unit award which will vest in there equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F2 · derivative.exercise_date: The award was a restricted stock unit award which will vest in there equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F2 · derivative.expiration_date: The award was a restricted stock unit award which will vest in there equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2022 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 20:40 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 43,199 | $0.00 Strike: $65.11 | $0.00 |
DisclosureSEC source: 0001209191-22-018841 · doc4.xml · derivative · entry 1 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,199 Underlying: Common Stock · 43,199 shares Expires 2030-03-11 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/11/2022. Read SEC document |
| January 18, 2022 Filed Jan 19, 2022 21:40 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantRestricted Stock Units · Derivative | 29,656 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003745 · doc4.xml · derivative · entry 1 De Witte Jan · CIK 0001776929 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,656 Underlying: Common Stock · 29,656 shares Expires not disclosed F1 · derivative.exercise_price: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 01/18/2022 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F1 · derivative.exercise_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 01/18/2022 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. F1 · derivative.expiration_date: The award was a restricted stock unit award which will vest in three annual equal installments on the first, second and third anniversaries of the grant date of 01/18/2022 which shall be delivered to Mr. De Witte within 30 days following the first business day that occurs immediately following the six month period after the date of his separation of service as deferred compensation. This award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 23:53 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 956 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-21-000034 · primary_doc.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,989 F1 · shares: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2022, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:03 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingReMed Common Stock | 104 | $259.47 | $26,984.88 |
DisclosureSEC source: 0001127602-21-029093 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,033 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/19/2020. Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 20:56 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingReMed Common Stock | 183 | $212.11 | $38,816.13 |
DisclosureSEC source: 0001127602-20-030106 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,137 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 00:08 UTC | RESMED INC RMD · Entity 2692 | GrantReMed Common Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-029759 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,320 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2021, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 19:06 UTC | RESMED INC RMD · Entity 2692 | GrantReMed Common Stock | 1,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033656 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,133 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2020, or the annual shareholders meeting in the year following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.